ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimusITM plans...

Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection Curium advances cancer care with its 505(b)(2) NDA submission to the FDA for Lutetium Lu 177 Dotatate Injection in GEP-NETS patients.

ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference Garching / Munich, March 16, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the company will present an overview of genetic...

ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs) Garching / Munich, October 27, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) has...